Related Experiment Videos
Venlafaxine-associated interstitial pneumonitis
Rachel C Turner1, Jeffery E Nelson, Bruce T Roberts
1Departments of Pharmacy, Blount Memorial Hospital, 907 East Lamar Alexander Parkway, Maryville, TN 27804-5016, USA.
Pharmacotherapy
|June 28, 2005
Summary
Venlafaxine may trigger extrinsic allergic alveolitis, a lung condition causing shortness of breath. Discontinuing the drug and using corticosteroids improved a patient's symptoms and lung infiltrates.
Area of Science:
- Pulmonology
- Pharmacology
- Toxicology
Background:
- Interstitial pneumonitis is a group of lung diseases that cause scarring (fibrosis) of the lungs.
- Extrinsic allergic alveolitis (EAA) is an immune system disorder caused by inhaling certain substances.
- Venlafaxine is an antidepressant medication commonly prescribed for depression and anxiety disorders.
Observation:
- A 55-year-old woman presented with a 7-month history of progressive dyspnea on exertion and hypoxia.
- Her symptoms began after a dosage increase of venlafaxine.
- Computed tomography (CT) scans revealed ground-glass opacities, and a lung biopsy confirmed interstitial pneumonitis consistent with EAA.
Findings:
- Discontinuation of venlafaxine and initiation of corticosteroid therapy led to improvement in the patient's hypoxia and reduction of lung infiltrates.
- Exclusion of other potential etiologies supported venlafaxine as the causative agent.
- This case suggests a potential link between venlafaxine use and the development of EAA.
Implications:
- Venlafaxine should be considered as a potential trigger for extrinsic allergic alveolitis in patients presenting with compatible symptoms and imaging findings.
- Early recognition and drug withdrawal are crucial for managing drug-induced lung disease.
- Further research is warranted to elucidate the mechanisms underlying venlafaxine-induced EAA and to establish diagnostic criteria.